This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lebovitz, H. E Search for Related Content Social Bookmarking                   What's this?

Review: Type 2 diabetes: how far have we come?

State University of New York Health Science Centre at Brooklyn, 416 Henderson Avenue, Staten Island, NY 10310, USA, hlebovitz{at}attglobal.net

The last 50 years has witnessed the recognition of type 2 diabetes as a complex heterogeneous disease that results from an interaction between environmental factors and genetic predispositions. As its pathophysiology has been unfolded by the advances in clinical science, so its prevalence has increased dramatically, and it is now one of the major personal and public health problems worldwide. Therapeutic approaches to address insulin resistance and beta-cell dysfunction have intensified and diversified during the last decade, driven by indisputable evidence that the treatment goals include both glycaemic control and attention to all vascular risk factors. Advances in basic and clinical research over the last fifty years have culminated in sufficient strategies and pharmacological agents to start to achieve these goals. Equally as important, they have laid the foundation for what promise to be remarkable future developments.

Key Words: treatment and prevention of type 2 diabetes • insulin resistance • insulin deficiency • metabolic syndrome.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 6, 446-449 (2002)
DOI: 10.1177/14746514020020060601


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?